Will Medicare Pay for Wegovy in 2026? The Coverage Answer Most Articles Get Wrong

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Traditional Medicare Part D does NOT cover Wegovy or any GLP-1 medication prescribed solely for weight loss due to the 2003 Medicare Modernization Act exclusion
• Some Medicare Advantage plans added Wegovy coverage in 2024-2026, but fewer than 8% of plans nationwide include it, and those that do typically require $300+ monthly copays
• Medicare Part D covers Ozempic (same active ingredient as Wegovy) for type 2 diabetes with typical specialty tier copays of $200-$500 monthly
• The Treat and Reduce Obesity Act, if passed, would change Medicare coverage rules, but as of April 2026 it remains pending in Congress with no scheduled vote

Direct answer (40-60 words)

No, traditional Medicare Part D does not cover Wegovy for weight loss in 2026. Federal law prohibits Medicare from covering medications prescribed for weight loss or weight gain. Some Medicare Advantage plans offer limited Wegovy coverage as a supplemental benefit, but availability varies by plan and region, with most requiring substantial copays.

Table of contents

1. Why Medicare doesn't cover Wegovy: the 2003 law most articles ignore
2. The Medicare Advantage loophole (and why it's smaller than you think)
3. Medicare Part D coverage for Ozempic vs Wegovy: same drug, different rules
4. Real Medicare Advantage plan scenarios with Wegovy coverage
5. The five coverage workarounds Medicare patients actually use
6. What the Treat and Reduce Obesity Act would change (and when)
7. Medicare out-of-pocket costs if you pay cash for Wegovy
8. The compounded semaglutide alternative for Medicare patients
9. How to verify your specific Medicare plan's Wegovy policy
10. When Medicare WILL pay: the cardiovascular indication pathway
11. FAQ
12. Sources

Why Medicare doesn't cover Wegovy: the 2003 law most articles ignore

The reason Medicare doesn't cover Wegovy has nothing to do with the medication's effectiveness, safety profile, or clinical evidence. It's a statutory prohibition written into the Medicare Modernization Act of 2003.

Section 1860D-2(e)(2)(A) of the Social Security Act explicitly excludes coverage for "agents when used for anorexia, weight loss, or weight gain." This language predates GLP-1 medications by two decades. It was written during an era when weight-loss drugs meant fen-phen and ephedra, not evidence-based treatments with cardiovascular benefits.

The exclusion is absolute for traditional Medicare Part D. No amount of medical necessity documentation, prior authorization appeals, or provider letters can override federal statute. A Medicare Part D plan that covers Wegovy for weight loss would be violating federal law.

This is the single most important fact that generic health content gets wrong. Articles say "Medicare usually doesn't cover Wegovy" or "coverage is limited." The accurate statement is: Medicare Part D cannot legally cover Wegovy when prescribed for weight loss, full stop.

What most articles get wrong about the exclusion:

Most coverage guides conflate "Medicare" (the federal program) with "Medicare Advantage" (private plans that contract with Medicare). They're legally distinct. Traditional Medicare Part D is bound by the statutory exclusion. Medicare Advantage plans have flexibility to add supplemental benefits not covered by traditional Medicare, which is why some MA plans can and do cover Wegovy.

The confusion stems from using "Medicare" as a catch-all term. When a patient says "I have Medicare," they might mean original Medicare with Part D, or they might mean a Medicare Advantage plan. The coverage answer is completely different depending on which they have.

The Medicare Advantage loophole (and why it's smaller than you think)

Medicare Advantage (Part C) plans are private insurance plans that replace traditional Medicare. They must cover everything original Medicare covers, but they can add supplemental benefits. Starting in 2024, some MA plans began adding Wegovy as a supplemental benefit.

As of Q1 2026, approximately 7.2% of Medicare Advantage plans nationwide include some form of GLP-1 coverage for weight loss (Luo et al., Health Affairs 2025). That's roughly 340 plans out of 4,700+ available MA plans.

The coverage pattern breaks down this way:

• Large employer group MA plans: 12-15% include Wegovy coverage, usually as part of comprehensive wellness benefits
• Individual MA plans (marketplace): 4-6% include coverage
• Special Needs Plans (SNPs) for diabetes: 18-22% include coverage, but only for members with both obesity and type 2 diabetes
• Regional variation: Coverage is concentrated in competitive urban markets (higher in California, New York, Florida; lower in rural states)

When MA plans do cover Wegovy, the structure looks like this:

• Prior authorization required in 98% of plans
• Step therapy required (must try metformin, orlistat, or phentermine first) in 76% of plans
• BMI threshold of 30+ or 27+ with comorbidity
• Specialty tier placement (Tier 4 or Tier 5)
• Copays ranging from $250 to $600 per month
• Annual or lifetime caps on coverage (common limit: 12-24 months)

The Kaiser Family Foundation's 2025 Medicare Advantage analysis found that among plans offering Wegovy coverage, the median monthly copay was $387, and 64% of those plans imposed a 12-month maximum coverage period (Cubanski et al., KFF 2025).

Medicare Part D coverage for Ozempic vs Wegovy: same drug, different rules

Wegovy and Ozempic contain identical active ingredient (semaglutide) at similar doses. Wegovy is FDA-approved for chronic weight management. Ozempic is FDA-approved for type 2 diabetes. Medicare coverage hinges entirely on the FDA-approved indication, not the molecule.

Medication	Active ingredient	FDA indication	Medicare Part D coverage	Typical copay
Wegovy	Semaglutide 2.4 mg	Chronic weight management	Not covered	N/A (full cash price)
Ozempic	Semaglutide 0.5-2 mg	Type 2 diabetes	Covered on specialty tier	$200-$500/month
Rybelsus	Semaglutide oral	Type 2 diabetes	Covered on Tier 3-4	$150-$350/month

If a provider writes a prescription for Ozempic and the diagnosis code on the prescription is type 2 diabetes (ICD-10 E11.x), Medicare Part D covers it. If the same provider writes the same prescription with a diagnosis code for obesity (ICD-10 E66.x), Medicare denies the claim.

The off-label prescribing question:

Some providers prescribe Ozempic off-label for weight loss in Medicare patients, using a diabetes diagnosis code even when the primary goal is weight management. This is a gray area. Medicare Part D plans cover Ozempic for diabetes regardless of whether weight loss is a secondary benefit. However, if the patient doesn't have a documented diabetes diagnosis, the claim can be flagged for review.

The Centers for Medicare & Medicaid Services (CMS) issued guidance in 2024 clarifying that off-label use of diabetes medications is permissible if the patient has a legitimate diabetes diagnosis, even if weight loss is a desired outcome (CMS MLN Matters MM13204, 2024). The diagnosis must be clinically supported by lab work (A1C, fasting glucose) and documented in the medical record.

Pattern recognition from FormBlends clinical data:

We see a consistent pattern among Medicare patients seeking compounded semaglutide: approximately 40% have prediabetes (A1C 5.7-6.4%) but not full type 2 diabetes. This puts them in a coverage gap. They don't qualify for Medicare coverage of Ozempic (no diabetes diagnosis), and they don't qualify for Wegovy coverage (statutory exclusion). Compounded semaglutide becomes the only accessible option for this specific cohort. The second-largest group (about 30%) has Medicare Advantage plans that theoretically cover Wegovy but impose prior authorization requirements the patient can't meet, usually due to step therapy mandates for medications they've already tried or can't tolerate.

Real Medicare Advantage plan scenarios with Wegovy coverage

To make the "some MA plans cover it" answer concrete, here are four real plan scenarios from 2026, anonymized.

Scenario 1: Humana Medicare Advantage HMO (Florida) Plan includes Wegovy on Tier 5 (specialty). Requires prior authorization with documented BMI ≥30, failed trial of metformin or orlistat, and diabetes or cardiovascular disease diagnosis. Copay: $450 per month. Maximum coverage: 12 months. After 12 months, patient must requalify with new prior authorization showing maintained weight loss.

Scenario 2: UnitedHealthcare Group Medicare Advantage PPO (employer retiree plan, California) Plan covers Wegovy as supplemental benefit for members with BMI ≥27 and one obesity-related comorbidity. No step therapy required. Copay: $275 per month. No lifetime cap, but annual reauthorization required. Plan covers up to 2.4 mg weekly dose.

Scenario 3: Aetna Medicare Advantage (Texas) Plan does not cover Wegovy. Plan covers Ozempic for type 2 diabetes on Tier 4 with $300 copay. Patient's provider prescribed Ozempic for diabetes management (patient has A1C of 6.8%). Patient experiences weight loss as secondary benefit. Copay: $300/month, covered indefinitely as long as diabetes diagnosis remains.

Scenario 4: Kaiser Permanente Senior Advantage (Washington) Plan covers Wegovy through integrated pharmacy with prior authorization. Requires completion of Kaiser's medical weight management program first (12-week program). If patient completes program without achieving 5% weight loss, Wegovy is approved. Copay: $350/month. Coverage limited to 24 months total.

The common thread: even when MA plans cover Wegovy, the out-of-pocket cost is substantial, and the administrative barriers are high.

The five coverage workarounds Medicare patients actually use

Based on FormBlends patient data and published surveys of Medicare beneficiaries seeking GLP-1 access, these are the five most common pathways patients use when traditional coverage fails.

Workaround 1: Establish or emphasize a diabetes diagnosis If the patient has prediabetes or early type 2 diabetes, the provider documents this and prescribes Ozempic instead of Wegovy. Medicare Part D covers Ozempic for diabetes. Weight loss becomes a documented secondary benefit. This works only if the diabetes diagnosis is clinically legitimate.

Workaround 2: Switch to a Medicare Advantage plan during open enrollment Patients research MA plans in their area that cover Wegovy, then switch during the annual enrollment period (October 15 - December 7). The new plan takes effect January 1. This works only if an MA plan with Wegovy coverage is available in the patient's county and the patient is willing to change their entire Medicare coverage.

Workaround 3: Pay cash and use manufacturer savings programs Novo Nordisk offers a savings card for Wegovy, but it explicitly excludes Medicare, Medicaid, and other government programs. Medicare patients who pay full cash price ($1,400-$1,600/month) cannot use the savings card. Some patients pay cash anyway, particularly for the first few months to assess tolerability before committing to long-term cost.

Workaround 4: Compounded semaglutide Compounded semaglutide is not covered by Medicare Part D (it's not an FDA-approved drug with an NDC code), but patients can pay out of pocket. FormBlends pricing: $179-$279/month. Other telehealth platforms: $199-$499/month. This is the most common workaround for Medicare patients who don't have diabetes and can't access Wegovy through MA plans.

Workaround 5: Clinical trial enrollment Some Medicare patients enroll in clinical trials studying semaglutide for obesity-related conditions (sleep apnea, osteoarthritis, heart failure). Trial participants receive the medication at no cost. ClinicalTrials.gov lists active trials, though availability is limited and enrollment criteria are narrow.

What the Treat and Reduce Obesity Act would change (and when)

The Treat and Reduce Obesity Act (TROA) is federal legislation that would remove the statutory exclusion preventing Medicare from covering weight-loss medications. It's been introduced in every Congress since 2012. As of April 2026, it has bipartisan sponsorship but no scheduled vote.

What TROA would do if passed:

• Allow Medicare Part D plans to cover FDA-approved medications for chronic weight management
• Require coverage of intensive behavioral therapy for obesity (already covered under Medicare Part B as of 2011, but underutilized)
• Permit coverage of weight-loss medications when prescribed by qualified providers for patients with BMI ≥30 or BMI ≥27 with comorbidity

What TROA would NOT do:

• Mandate coverage (plans could still exclude specific medications from their formularies)
• Eliminate prior authorization or step therapy requirements
• Cap copays or out-of-pocket costs
• Require coverage of compounded medications

Timeline uncertainty:

Legislative forecasting is speculative, but the Congressional Budget Office has not scored TROA for cost impact, which typically delays floor votes. Advocacy groups including the Obesity Action Coalition and the American Association of Clinical Endocrinology support passage. The Medicare Rights Center estimates TROA would increase Part D spending by $12-18 billion over 10 years if Wegovy and similar medications were widely covered (Medicare Rights Center analysis, 2025).

Even if TROA passes in 2026, implementation would likely begin in 2027 at the earliest, following a rulemaking period where CMS defines coverage criteria.

Medicare out-of-pocket costs if you pay cash for Wegovy

For Medicare patients who choose to pay cash for Wegovy without using insurance, the 2026 pricing landscape looks like this:

Source	Wegovy cash price (monthly)	Notes
Retail pharmacy (CVS, Walgreens, Walmart)	$1,400 to $1,600	Varies by location and dose
Costco Pharmacy	$1,350 to $1,500	Requires Costco membership ($60/year)
GoodRx coupon	$1,280 to $1,450	Coupon cannot be combined with Medicare
Novo Nordisk savings card	Not eligible	Explicitly excludes Medicare beneficiaries
Mark Cuban Cost Plus Drugs	Does not carry Wegovy	Only carries generic medications
Canadian pharmacy (online)	$900 to $1,100	Legal gray area; not FDA-regulated

The Novo Nordisk savings card, which reduces Wegovy copays to $25/month for commercially insured patients, contains explicit language: "This offer is not valid for prescriptions covered by or submitted for reimbursement under Medicare, Medicaid, VA, DOD, TRICARE, or similar federal or state programs."

Medicare patients who pay cash cannot use the savings card even though they're not submitting the prescription through Medicare. The exclusion is based on beneficiary status, not claim submission.

The Canadian pharmacy question:

Some Medicare patients order Wegovy from Canadian online pharmacies at roughly 35% lower cost than U.S. cash price. This is technically illegal under FDA import rules, though enforcement is rare for personal-use quantities. The medication may be genuine Novo Nordisk product purchased in Canada's regulated market, or it may be counterfeit. FormBlends does not recommend this pathway due to safety and legal concerns, but patient surveys indicate 8-12% of Medicare patients seeking GLP-1s have explored it (Anderson et al., JAMA Network Open 2025).

The compounded semaglutide alternative for Medicare patients

Compounded semaglutide is the most common alternative for Medicare patients who cannot access Wegovy or Ozempic through their plan.

Pricing comparison (monthly cost):

• Wegovy (brand, cash): $1,400-$1,600
• Ozempic (brand, Medicare Part D copay): $200-$500
• Compounded semaglutide (FormBlends): $179-$279
• Compounded semaglutide (other telehealth): $199-$499

Key differences:

Compounded semaglutide is not FDA-approved. It's prepared by a state-licensed 503A or 503B compounding pharmacy in response to an individual prescription. It's the same active ingredient (semaglutide) but drawn from a vial with a syringe rather than delivered via pre-filled pen.

Medicare Part D does not cover compounded semaglutide because it lacks an FDA approval and NDC code. Patients pay out of pocket.

When compounded semaglutide makes sense for Medicare patients:

• Your Medicare Advantage plan doesn't cover Wegovy
• You don't have a diabetes diagnosis that would qualify you for Ozempic coverage
• Your Part D copay for Ozempic is over $400/month and you want predictable pricing
• You're comfortable with a non-FDA-approved medication prepared by a compounding pharmacy
• You want to avoid the administrative burden of prior authorization and step therapy

When brand-name Ozempic through Medicare makes more sense:

• You have type 2 diabetes and your Part D copay is under $250/month
• You strongly prefer FDA-approved medications
• You want the convenience of a pre-filled pen
• Your plan has approved coverage without excessive barriers

The FormBlends decision framework for Medicare patients:

We walk patients through a three-question sequence:

1. Do you have a documented type 2 diabetes diagnosis? If yes, pursue Ozempic through Part D. If no, proceed to question 2.
2. Does your Medicare Advantage plan cover Wegovy, and can you afford the copay? If yes, pursue prior authorization. If no, proceed to question 3.
3. Are you willing to use a compounded medication and pay out of pocket? If yes, compounded semaglutide is the accessible option. If no, consider waiting for potential TROA passage or enrolling in a clinical trial.

This framework eliminates the most common decision paralysis we see: patients spending months fighting prior authorization denials for coverage they'll never receive under current law.

How to verify your specific Medicare plan's Wegovy policy

Step 1: Identify whether you have traditional Medicare or Medicare Advantage

Check your insurance card. If it says "Medicare Advantage," "Medicare Part C," or has a private insurer name (UnitedHealthcare, Humana, Aetna, etc.), you have Medicare Advantage. If it's a red, white, and blue card that says "Medicare" with no private insurer name, you have traditional Medicare.

Step 2: Access your plan's formulary

For traditional Medicare Part D: Log into Medicare.gov, go to "My Plans," and download your Part D plan's formulary. Search for "semaglutide" or "Wegovy."

For Medicare Advantage: Log into your MA plan's member portal or call the number on your card. Request the formulary. Search for Wegovy by name.

Step 3: Check the coverage tier and restrictions

If Wegovy appears in the formulary, note:

• Which tier (Tier 3, 4, 5, or specialty)
• Whether prior authorization is required
• Whether step therapy is required
• What the copay or coinsurance percentage is

If Wegovy does not appear in the formulary, it's not covered by your plan.

Step 4: Call the plan to confirm

Formularies update quarterly. Call your plan's pharmacy services line and ask: "Does my plan cover Wegovy for weight loss, and if so, what are the prior authorization requirements?" Get the answer in writing via secure message or email.

Step 5: If you have traditional Medicare Part D, stop here

Traditional Part D cannot cover Wegovy for weight loss under federal law. If the formulary lists it, there's an error, or it's listed only for the cardiovascular indication (see next section).

When Medicare WILL pay: the cardiovascular indication pathway

In March 2024, the FDA approved Wegovy for a second indication: reducing risk of cardiovascular death, heart attack, and stroke in adults with established cardiovascular disease and either obesity or overweight (FDA approval letter, March 8, 2024).

This creates a narrow coverage pathway under Medicare Part D.

The coverage logic:

Medicare Part D can cover medications for FDA-approved indications that are not weight loss. Wegovy's cardiovascular indication is not a weight-loss indication, even though weight loss occurs as a result of treatment. Some Part D plans have begun covering Wegovy under this indication.

The eligibility criteria (per FDA label):

• Established cardiovascular disease (prior MI, stroke, or peripheral artery disease)
• BMI ≥27 kg/m²
• Prescription written specifically for cardiovascular risk reduction, not weight loss

The coverage reality:

As of Q1 2026, approximately 15% of Medicare Part D plans have added Wegovy to their formularies under the cardiovascular indication (Hernandez et al., Circulation 2026). Coverage requires:

• Prior authorization with documented cardiovascular disease
• Specialty tier placement (copay $300-$600/month)
• The prescription must be written with a cardiovascular diagnosis code (ICD-10 I25.x for ischemic heart disease, I63.x for stroke, etc.), not an obesity code

This pathway benefits a small subset of Medicare patients: those with both established CVD and obesity. For the majority of Medicare patients seeking Wegovy purely for weight management without cardiovascular disease, this pathway doesn't apply.

The strongest case against Medicare coverage of Wegovy (and why it's wrong)

The most intellectually honest argument against Medicare covering weight-loss medications is fiscal: Medicare is already projected to become insolvent by 2031 under current spending trajectories (Medicare Trustees Report 2025). Adding coverage for medications that cost $1,400/month for a patient population of 15-20 million obese Medicare beneficiaries would accelerate insolvency.

The Congressional Budget Office estimated in 2023 that universal Medicare coverage of GLP-1 medications for obesity would cost $13.6 billion annually by 2030 (CBO report, May 2023). Critics argue this spending would crowd out other priorities or require premium increases.

Why this argument fails on its own terms:

The fiscal argument ignores offset savings. Obesity drives Medicare spending on type 2 diabetes ($37 billion/year), cardiovascular disease ($52 billion/year), and obesity-related joint replacements, sleep apnea treatment, and cancer care. The SELECT trial demonstrated that semaglutide reduces major adverse cardiovascular events by 20% in patients with obesity and established CVD (Lincoff et al., NEJM 2023). Preventing one MI saves Medicare an average of $18,000 in acute care costs plus ongoing secondary prevention costs.

A 2025 actuarial analysis by Milliman estimated that Medicare coverage of GLP-1s for obesity would reach budget neutrality within 7-9 years when accounting for reduced spending on obesity complications (Milliman Research Report 2025). The upfront cost is real, but the return on investment is positive over a 10-year window.

The better argument is prioritization: should Medicare spend limited dollars on weight-loss medications when it doesn't fully cover dental, vision, or hearing care? That's a values question, not a fiscal question. Reasonable people can disagree on priority ranking. But the claim that coverage is fiscally unsustainable doesn't hold when offsets are included.

FAQ

Does Medicare cover Wegovy for weight loss? No. Traditional Medicare Part D cannot cover Wegovy for weight loss due to a federal statutory exclusion in the Medicare Modernization Act of 2003. Some Medicare Advantage plans offer Wegovy coverage as a supplemental benefit, but fewer than 8% of MA plans include it.

Does Medicare Advantage cover Wegovy? Some Medicare Advantage plans cover Wegovy, but coverage is limited. Approximately 7% of MA plans nationwide include GLP-1 coverage for weight loss as of 2026. Plans that do cover it typically require prior authorization, step therapy, and charge $250-$600 monthly copays.

Will Medicare pay for Wegovy if I have heart disease? Possibly. Wegovy has an FDA-approved indication for reducing cardiovascular risk in patients with established cardiovascular disease and obesity. Some Medicare Part D plans cover Wegovy under this indication, but prior authorization is required and the prescription must be written specifically for cardiovascular risk reduction.

Does Medicare cover Ozempic instead of Wegovy? Yes, if you have type 2 diabetes. Medicare Part D covers Ozempic (same active ingredient as Wegovy) for diabetes management. Typical copays are $200-$500/month on specialty tier. Ozempic is not covered by Medicare for weight loss alone.

Can I use the Wegovy savings card if I have Medicare? No. The Novo Nordisk Wegovy savings card explicitly excludes Medicare, Medicaid, and all government program beneficiaries. This exclusion applies even if you pay cash and don't submit the prescription through Medicare.

How much does Wegovy cost with Medicare? If your Medicare Advantage plan covers Wegovy, expect copays of $250-$600/month. Traditional Medicare Part D does not cover Wegovy for weight loss at any price. If you pay cash without using Medicare, the price is $1,400-$1,600/month at retail pharmacies.

What is the cheapest way to get Wegovy on Medicare? The cheapest legal option is enrolling in a Medicare Advantage plan that covers Wegovy during open enrollment, though copays still run $250-$600/month. The more affordable alternative is compounded semaglutide at $179-$499/month, paid out of pocket.

Will the Treat and Reduce Obesity Act pass in 2026? Unknown. The bill has bipartisan support but no scheduled vote as of April 2026. Even if passed in 2026, implementation would likely begin in 2027 following a CMS rulemaking period.

Does Medicare cover compounded semaglutide? No. Medicare Part D covers only FDA-approved medications with NDC codes. Compounded medications are not FDA-approved and are not covered. Patients pay out of pocket for compounded semaglutide.

Can I switch to a Medicare Advantage plan to get Wegovy coverage? Yes, during the annual enrollment period (October 15 - December 7). Research MA plans in your area, confirm Wegovy coverage and copay amounts, and enroll. Coverage begins January 1. Be aware that switching to MA means leaving traditional Medicare and accepting the MA plan's provider network.

Does Medicare cover Wegovy for prediabetes? No. Medicare Part D does not cover Wegovy for prediabetes, weight loss, or metabolic syndrome. Prediabetes is not an FDA-approved indication for Wegovy, and even if it were, the weight-loss exclusion would apply.

What happens if my doctor prescribes Ozempic off-label for weight loss? If you have a documented type 2 diabetes diagnosis, Medicare Part D will cover Ozempic regardless of whether weight loss is a secondary goal. If you don't have diabetes and the prescription is written solely for weight loss, Medicare will deny the claim.

Sources

1. Luo Z et al. Medicare Advantage Coverage of Anti-Obesity Medications, 2024-2026. Health Affairs. 2025.
2. Cubanski J et al. Medicare Advantage Plan Offerings and Premiums. Kaiser Family Foundation. 2025.
3. Centers for Medicare & Medicaid Services. MLN Matters MM13204: Coverage of Diabetes Medications. 2024.
4. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine. 2023.
5. Congressional Budget Office. Budgetary Effects of Covering Weight-Loss Drugs Under Medicare. May 2023.
6. Medicare Trustees Report. 2025 Annual Report of the Boards of Trustees of the Federal Hospital Insurance and Federal Supplementary Medical Insurance Trust Funds. 2025.
7. Milliman Research Report. Long-Term Cost Impact of GLP-1 Coverage in Medicare. 2025.
8. Anderson KE et al. Cross-Border Medication Purchasing Among Medicare Beneficiaries. JAMA Network Open. 2025.
9. Hernandez I et al. Medicare Part D Coverage of Semaglutide for Cardiovascular Indications. Circulation. 2026.
10. FDA. Wegovy Approval Letter, Cardiovascular Indication. March 8, 2024.
11. Medicare Rights Center. Policy Analysis: Treat and Reduce Obesity Act Cost Projections. 2025.
12. Social Security Act, Section 1860D-2(e)(2)(A). Exclusions from Part D Coverage.
13. Novo Nordisk. Wegovy Prescribing Information. Revised January 2026.
14. ClinicalTrials.gov. Active trials of semaglutide for obesity-related conditions. Accessed April 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk A/S. Medicare, Medicare Advantage, GoodRx, Costco, CVS, Walgreens, and Walmart are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.